Skip to main content
NCBI home page
Orphanet Journal of Rare Diseases logoLink to Orphanet Journal of Rare Diseases
. 2024 Feb 24;19:85. doi: 10.1186/s13023-024-03078-0

Impact of neurofibromatosis type 1 on quality of life using the Skindex-29 questionnaire quality of life in NF1

Ana M Cieza Rivera 1, Carlos Lobato Fuertes 2, Tania Fernández-Villa 1,3,4, Vicente Martín Sánchez 1,3,4, Isis Atallah 1,5,✉
PMCID: PMC10893671  PMID: 38402381

Abstract

Background

Neurofibromatosis type 1 (NF1) is one of the most common RASopathies predisposing affected patients to melanic lesions and benign tumors. NF1 is associated with considerable esthetic and functional burden negatively affecting the patient’s quality of life (QoL). This study aims to assess the clinical features of NF1 patients and evaluate their impact on QoL. We identified NF1 patients from a public health database of a region in Spain. All patients underwent clinical and ophthalmological evaluation for NF1 features. We measured QoL using the Spanish version of the Skindex-29.

Results

Forty patients fulfilled the NF1 National Institute of Health criteria when we recruited patients. The median age was 42.00 years (IQR 26.5 -53.75). The median total Skindex-29 score was 12.3 (IQR 5.9–22.4); (emotion: 15.0, IQR 5.0-37.5; symptoms 8.9, IQR 0.0-17.9 and functioning 8.3; IQR 0.5–18.3). Women and NF1 patients with lower educational levels were associated with poorer QoL scores. We identified itching and sleep troubles to influence NF1 patients’ QoL negatively.

Conclusion

NF1 considerably influences the psychological well-being of NF1 patients. We observed that female and low-educated patients scored higher on the emotional dimension of the Skindex-29 and could, therefore, be more at risk of depression. We also pointed out some “minor symptoms” that negatively impact NF1 patients’ QoL such, as itching and sleep troubles which doctors could treat if sought by doctors.

Supplementary Information

The online version contains supplementary material available at 10.1186/s13023-024-03078-0.

Keywords: Quality of life, Skindex-29, Neurofibromatosis 1, Emotion, Symptoms, Functioning

Background

Neurofibromatosis type 1 (NF1; OMIM# 162,200) is one of the most common autosomal dominant disorders with a prevalence of one in 2,500 to 3,000 individuals. It is characterized by café au lait spots, axillary freckling, Lisch nodules, dermal or plexiform neurofibromas, skeletal dysplasia, and optic gliomas [1]. As NF1 is a tumor suppressor gene, 99% of NF1 patients develop benign tumors such as cutaneous neurofibromas, starting from puberty and increasing in size and number with age, pregnancy, or stress [2–4] or plexiform neurofibromas which are congenital tumors that can bulk at any time during life [1]. NF1 patients are also at risk of developing malignancies such as neurofibrosarcomas, pheochromocytomas, or breast cancer. With a complete penetrance and a high variability, the progression of the disease is unpredictable [5, 6]. In addition to disease burden, NF1 patients may suffer from stigmatization due to the unesthetic aspect and the visibility of the lesions, which might influence their physical, emotional, and social well-being. Studying the effects of NF1 on various aspects of quality of life (QoL) is important to implement beneficial strategies to improve the QoL of NF1 patients. Researches have used several questionnaires to study the QoL of NF1 patients primarily by post, mail or online surveys (SF-36, Skindex-29, NF1-AdQoL, WHOQOL-100, WHOQOL-Bref, cNF-Skindex, EQ-5D-5 L, INF1-QOL, PedsQL, DLQI, BoN, CHQ-PF50, ITQOL… ) [7–22]. In those studies, the QoL of individuals with NF1 was systematically below the QoL of the general population.

The purpose of this study was to assess the QoL of a phenotypically and clinically well-described cohort of adult individuals with NF1 to evaluate the impact of the different symptoms in their QoL. We used the Skindex-29, a skin disease-specific QoL questionnaire [23] used worldwide.

Methods

Study population

We identified NF1 patients by using the database of the Public Health Primary Care system and the database from the Leon main Hospital (Complejo Asistencial Universitario de Leon) by looking for the following items:

“Neurofibromatosis”, “Neurofibromatosis type 1”, “dermal neurofibroma”, " plexiform neurofibroma” and “neurofibrosarcoma”. We identified 106 patients fulfilling one of the mentioned criteria. We excluded patients with a diagnosis of neurofibromatosis type 2, carrying solitary tumors, or living outside the Leon public health. 16 patients were already deceased. We contacted patients by post and telephone. We could not get in contact with 18 patients and 14 patients refused to participate (Fig. 1).

Fig. 1.

Fig. 1

Open in a new tab

Flow diagram for patient recruitment

We identified 45 patients with a diagnosis of NF1; we excluded four of them as children. Forty-one patients were enrolled in the study. NF1-expert clinicians and ophthalmologists examined all patients. A patient who did not fulfill the NF1 diagnosis criteria was excluded. Genetic analysis was available for 18 patients.

The Institutional Review Board and the Ethics Committee of Leon University Hospital approved the study protocol (approval number 1060).

Severity and visibility evaluation

We assessed disease severity using the Riccardi scale [24], which has 4 degrees of severity, with Grade 1 being the mildest form and Grade 4 the more severe. In Grade 1, patients have some of the diagnostic features of NF1 without any compromising health and well-being. In Grade 2, patients have some features that make disease evident without impacting their health and well-being. In grade 3, patients have features that can impact their well-being without significantly compromising health, and in grade 4, patients have « seriously compromised health and well-being in a permanent, unmanageable way.».

We evaluated the disease visibility in full-dressed patients by using the Ablond scale [25] which has 3 degrees of severity. In grade 1, the disease is not visible with clothes. In grade 2, the patient presents some visible neurofibromas on the undressed body areas such as the face, neck, and hands or mild scoliosis. In grade 3, the disease is evident as the patient presents numerous visible tumors, disfiguring tumors, and severe complications such as severe scoliosis or cecity due to optic glioma.

Quality of life measurement tool

The Spanish version of Skindex-29 [26], which the patient fulfilled during clinical evaluation, was used to measure the QoL of NF1 patients. The Skindex-29 has 29 items distributed in 3 domains which represent three specific aspects of skin disease: physical symptoms (items 1, 7, 10, 16, 18, 23 and 26), functioning (items 2, 4, 5, 8, 11, 14, 17, 19, 21, 24, 28 and 29) and emotions (items 3, 6, 9, 12, 13, 15, 20, 22, 25 and 27). Each item is rated on a 5-point Likert scale (never, rarely, sometimes, often, all the time). Scale scores were calculated by averaging the responses to items of a given domain. We standardized the scores to percentages. A higher score indicated a more significant effect of the disease. Individual results of Skindex-29 are available in Supplementary File 1.

Data analysis

Data analysis was performed using SPSS for Windows v.26.0 software (SPSS Inc. Chicago, IL USA). We used non-parametric tests due to the limited number of patients and the non-normal distribution. The data were expressed as median and IQR. For categorical variables, we applied Wilcoxon rank-sum tests and Kruskal-Wallis tests depending on the number of groups to be compared (2 or more than 2). We used Spearman’s rank coefficient correlation for continuous variables. P values of < 0.05 were considered as statistically significant. We used STATA16 to create Fig. 2.

Fig. 2.

Fig. 2

Open in a new tab

Distribution of mean Skindex-29 scores by sex and domains

Results

Sample characteristics

We have clinically evaluated forty patients. The main clinical features and sociodemographic characteristics of the NF1 individuals included in this cohort are summarized in Table 1. Detailed clinical characteristics are available in Table 2.

Table 1.

Sociodemographic and main clinical features of the NF1 individuals included in this study

N n %
Sex
Females 40 21 52.5
Males 40 19 47.5
Age (years)
< 35 40 17 42.5
35–54 40 14 35.0
>=55 40 9 22.5
Education level
Undergraduate 34 15 44.1
Vocational education 34 12 35.3
University degree 34 7 20.6
Clinical characteristics
Six or more café au lait macules 40 39 97.5
Axillary and/or inguinal freckling 40 38 95.0
Two or more neurofibromas 40 32 80.0
Plexiform neurofibroma 40 17 42.5
Two or more Lisch nodules 37 29 78.4
Optic pathway glioma 40 4 10.0
Osseous lesions 40 20 50.0
Family history 40 20 50.0
Neurocognitive features 40 18 45.0
Central Nervous System 40 14 35.0
Short stature (< P3) 40 14 35.0
Macrocephaly (> P97) 40 5 12.5
Emphysema 40 1 2.5
Pruritus 40 15 37.5
Hypomelanic macules 40 3 7.5
Dizziness 40 12 30
Sleeping troubles 40 10 25.0
Headaches 40 9 22.5
Myomas 21 4 19.0
Malignancies 40 4 10.0
Open in a new tab

Table 2.

Detailed clinical information of the 40 NF1 individuals included in this study

ID Age Sex Size HC cNF pNF CL F LN G Osseous FH Neurocognitive Education Others AS RS Genetic variant
1 28 M 165 59.5 0 Sacral plexus X X X 0 Scoliosis 0 Vocational Hemihypertophia, pruritus 3 3

c.6367G > T, p.E2123X

NM_000267.3
2 53 M 169.5 54 X 0 X X X 0 Scoliosis X TDAH, LD No studies Pheocromocitoma, pruritus 2 3 NA
3 34 F 158.5 57 X Popliteal X X X 0 S. scoliosis X LD Vocational Ophtalmic aneurysm, myomas, pruritus 3 2

c.4084 C > T; p.(Arg1362*)

NM_000267.3
4 60 M 185 62 X 0 X 0 X 0 S. scoliosis X 0 - 0 2 3 NA
5 22 F 171 60 X Back X X X 0 0 0 0 University Dizziness, Wolf-Parkinson-White, pruritus 2 2

c.2379delC,p.(Asn793fs*28)

NM_001042492.2
6 21 M 170 60 0 0 X X X 0 Scoliosis X 0 University Hydrocephaly 1 2

c.7012_7014del,

p.(Leu2338del)

NM_001042492.2
7 54 M 170 59 X Para-tracheal X NC 0 0 0 0 LD, AD University Insomnia 3 3

c.7012_7014del, p.(Leu2338del)

NM_001042492.2
8 46 M 174.5 56.5 0 0 0 X X 0 0 0 TDAH Vocational 0 1 1 NA
9 80 M 147 58 X 0 X X - 0 0 0 0 Primary Dizziness, headache, pruritus, GIST 2 3 NA
10 22 F 167 52.5 X 0 X X 0 0 0 0 LD, AD Vocational Sleeping troubles, asthenia 1 2 NA
11 21 F 160 57 0 0 X X X 0 Scoliosis 0 0 Vocational Sleeping troubles, asthenia, hypopigmented macules 2 1 NA
12 22 F 160 58 X Sacral plexus X X 0 0 0 0 LD, AD No studies Headache 2 3

c.1149 C > A,p.(Cys383*)

NM_001042492.2
13 25 M 169.5 58 X 0 X X X 0 Scoliosis X LD, TDAH Secondary 0 2 2 NA
14 48 F 154 55 X 0 X X X 0 Scoliosis X 0 Primary 0 3 3 NA
15 34 M 162 59 X 0 X X X 0 S.Kypho-scoliosis X 0 Vocational Pruritus 2 3

c.574 C > T,p.(Arg192*)

NM_000267.3
16 57 M 162 58.5 X Facial X X X 0 0 0 0 Secondary Sleeping troubles, headache 3 3 NA
17 17 M 161.5 54.5 0 0 X X 0 0 0 0 LD, TDAH Primary Hypofisis cyst 1 1 Typical 1.4 Mb NF1 deletion
18 51 M 170 59 X 0 X X 0 0 Kypho-scoliosis 0 LD Primary

Puritus, Headache, dizziness,

meningioma

 2 2 NA
19 44 F 163 60 X 0 X X X X S. scoliosis 0 0 - Hydrocephaly, pruritus, myomas, sleeping troubles 3 4 NA
20 34 F 155.4 55.6 X 0 X X X 0 0 X AD - Hypopigmented macules 1 2

c.6100dup,

p.(Thr2034Asnfs*26)

NM_001042492.2
21 42 M 191 59 X Ankle X X X X

Tibial dysplasia

S. scoliosis

 0 0 Vocational

Limb length difference, cerebral artery hypoplasia, pruritus

sleeping troubles

 3 3

c.5606T > G,p.(Leu1869*)

NM_001042492.2
22 61 M 165.9 59.3 X Gluteal X X X 0 S. scoliosis X 0 - Dizziness 2 2 NA
23 42 F 172.5 57 X 0 X 0 - 0 0 0 0 University 0 3 2 NA
24 43 M 163 56 X Right arm X X - 0 S. scoliosis 0 Hyperactivity Vocational 0 2 2

c.1986delA,

p.(Asn664Thrfs*24)

NM_001042492.2
25 21 F 151.5 54 X Sacral plexus X X 0 X Scoliosis X 0 Vocational Pruritus, Dizziness 3 4 NA
26 55 F 155 52.5 X Sacral plexus X X X 0 0 X LD, AD No studies Vertigo 1 2 NA
27 56 F 156 56 X 0 X X X 0 0 X 0 - Pruritus 2 2

c.574 C > T,p.(Arg192*)

NM_000267.3
28 43 F 149 56 X 0 X X X 0 0 0 0 University Myomas, pruritus 1 2 NA
29 63 F 144 51 X 0 X X X 0 Scoliosis X TDAH, LD No studies Myomas, sleeping troubles, headache 3 3

c.3826 C > T,p.(Arg1276*)

NM_001042492.2
30 53 F 143.5 53 X 0 X X X 0 0 X LD No studies Insomnia, asthenia depression, pruritus 3 3

c.3826 C > T,p.(Arg1276*)

NM_001042492.2
31 26 F 152.3 50.5 0

Facial, brachial

plexus

 X X 0 0 0 X LD, AD University Headache, hypopigmented macules 3 3 NA
32 32 M 173.4 50 X 0 X X X 0 0 0 LD, mild ID Vocational 0 2 3

c.7211del,

p.(Ala2404Valfs14)

NM_001042492.2
33 76 M 154 58 X Occipital X X X 0 0 0 LD No studies Dizziness, pruritus 2 2 NA
34 45 F 148 52.5 X 0 X X X 0 S. scoliosis X TDAH No studies

Headache uterine polype, dizziness, depression, pruritus

sleeping troubles

 3 3 NA
35 35 M 164 61 0 0 X X X 0 0 0 0 - Vertigo 1 1 NA
36 22 M 165.5 57.7 X Lumbo-sacreal X X 0 0 Sphenoid dysplasia X 0 Vocational 0 3 3 NA
37 58 F 164 55.5 X 0 X X X 0 0 X 0 Primary Ca mama y colon, headache, dizziness, myomas 3 4

c.6792 C > G,p.(Tyr2264*)

NM_000267.3
38 28 F 161 58 X Temporal X X X X Sphenoiddysplasia Kypho-scoliosis X 0 No studies Dizziness, headache 3 3

c.6792 C > G,p.(Tyr2264*)

NM_000267.3
39 29 F 142 54 X Breast, lumbo-sacreal X X X 0 0 0 0 Vocational Dizziness, depression, sleeping troubles 2 3

c.6709 C > T,p.(Arg2237*)

NM_000267.3
40 35 F 156 56 0 Abdominal X X 0 0 C.Scoliosis X 0 Vocational 0 1 2 NA
Open in a new tab

Disease severity/ disease visibility

Results of the Skindex-29 questionnaire, Ablond Index (AI), and Riccardi severity scores (RSS) are summarized in Table 3. Most patients had mild or minimal severity status (52.5%) and moderate disease visibility (42.5%).

Table 3.

Skindex-29 results in NF1 patients stratified by sex, age group, education level, disease visibility (Ablond’s score) and disease severity (Riccardi’s score)

N n % Total Emotions Physical symptoms Functioning
Sex
Females 40 21 52.5 19.0 (9.3–23.6) 25.0 (7.5–42.5) 10.7 (0.0-19.7) 12.5 (2.1–19.8)
Males 40 19 47.5 7.1 (4.0-18.6) 7.5 (5.0–20.0) 7.1 (0.0-17.9) 2.1 (0.0-12.5)
p value a 0.034 0.061 0.688 0.088
Age (years)
< 35 40 17 42.5 10.3 (6.0-21.3) 20.0 (5.0–35.0) 7.1 (0.0-14.3) 4.2 (0.0-18.7)
35–54 40 14 35.0 19.1 (6.0-25.9) 11.3 (5.0-51.3) 16.1 (0.0-36.6) 6.3 (0.0-20.4)
>=55 40 9 22.5 12.3 (4.2–21.9) 17.5 (6.3–37.5) 7.1 (0.0-14.3) 10.4 (2.0-15.7)
p value a 0.759 0.999 0.209 0.920
Ablond’s score
Grade 1 40 12 30.0 9.7 (5.3–20.7) 10.0 (5.0-36.3) 1.8 (0.0-13.4) 2.1 (0.0-15.6)
Grade 2 40 17 42.5 13.6 (6.6–24.0) 17.5 (6.3–37.5) 7.1 (1.8–23.2) 12.5 (1.1–16.7)
Grade 3 40 11 27.5 10.3 (2.6–30.6) 10.0 (5.0–50.0) 14.3 (0.0-21.4) 10.4 (2.0–25.0)
p value b 0.545 0.825 0.207 0.397
Riccardi’s score
Grade 1 40 5 12.5 6.4 (5.8–9.7) 5.0 (5.0–15.0) 10.7 (3.6–14.3) 2.1 (0.0-9.4)
Grade 2 40 16 40.0 11.0 (4.3–22.4) 15.0 (5.0–25.0) 3.6 (0.0-23.2) 3.2 (0.0-14.1)
Grade 3 40 15 37.5 18.6 (8.8–33.8) 25.0 (7.5–50.0) 14.3 (0.0-21.4) 12.5 (2.1–25.0)
Grade 4 40 4 10.0 13.4 (3.3–27.7) 21.3 (5.0-48.8) 10.7 (1.8–14.3) 8.4 (1.1.21.9)
p value b 0.202 0.173 0.876 0.130
Open in a new tab

a Contrast data by Spearman rank correlation. b Contrast data by Kruskal-Wallis.

Skindex-29

The median of Skindex-29 scores was 12.3 (IQR 5.9–22.4). Emotions items (median 15.0; IQR 5.0-37.5) scored higher than symptoms (median 8.9; IQR 0.0-17.9) and functioning (median 8.3; IQR 0.5–18.3). Figure 2 shows the results stratified by sex and domain (emotions, physical symptoms, and functioning). We observed an association between the emotion and functioning scores (p < 0.001) and between the symptoms and the functioning scores (p = 0.042). The 5 items with a higher score were Q13 “I worry that my skin condition might get worse” (85 points, emotion), Q12 “I am ashamed of my skin condition” (47 points, emotions), Q6 “My skin made me feel depressed” (44 points, emotion), Q5 “My skin affects my social life” (42 points, functioning), and Q10 “My skin itches” (40 points, symptoms).

Women showed higher scores on the Skindex-29 questionnaire (women: median 19.0; IQR 9.0-23.6 and men: median 7.1; IQR 4.0-18.6; p = 0.034) than men. We observed a trend for sex differences in emotion (woman: median 25.0; IQR 7.5–42.5 and men: median 7.5; IQR 5.0–20.0; p = 0.061) and functioning items women: median 12.5.; IQR 2.1 − 19.8 and men: median 2.1; IQR 0.00–12.50; p = 0.088). We did not observe sex differences for symptoms, disease severity, or disease visibility scores. Aging did not correlate with increased scores on emotions, functioning, or physical symptoms.

Fifteen NF1 individuals (37.5%) complained of itching. The presence of pruritus was associated with higher scores on the symptoms domain of the Skindex-29 questionnaire (p˂0.001). The sleep troubles described in 10 NF1 individuals (25%) significantly impacted the Skindex-29 scores on the functioning (p = 0.013) and symptoms domains (p = 0.047).

Discussion

Improving the QoL of our patients is an essential objective for all physicians and health workers. This objective is even more important in patients with rare disorders as they must frequently deal with ignorance and incomprehension.

Several QoL questionnaires have been used and developed worldwide for the NF1 population. However, standardization is needed to compare the QoL of NF1 patients from different regions or countries. There are only a few studies that have assessed QoL in NF1 patients with the Skindex-29 questionnaire: in France [27], Italy [10], the USA [18], and Australia [7, 28, 29]. Compared to prior studies, we observed a lower impact of NF1 in the QoL of the patients described in this study, as their scores were lower than in earlier reports. The emotional dimension was significantly more impacted than the other dimensions, consistent with previous studies. The different impacts of NF1 in those studies could reflect differences in enrollment, population, disease staging, demographic differences, health care system, and study design. All NF1 individuals included in this study were identified from a primary care unit or reference hospital in a semi-urban area where patients are followed mainly by general practitioners and dermatologists and may, therefore, be more representative of the general population than patients in a Neurofibromatosis clinic. Furthermore, Spain has a public health system, which might contribute to facilitating access to medical care and lessen the financial burden of the disease and the impact on disease perception. We performed the clinical exam and administered the Skindex-29 at the same time point. Thus, Ablon’s visibility and Riccardi’s severity scores were assessed by physicians and not by the patient himself who could be biased by his own disease perception. However, the main limitation of this study is the small number of NF1 patients enrolled, which limited the statistical power of some findings.

The Skindex-29 questionnaire revealed that women with NF1 are more severely impacted than men. Sex differences in QoL in NF1 patients were previously observed [8, 18, 21]. Women with NF1 have higher scores on emotion, perceived physical appearance, anxiety, and mental health [8]. We also observed a strong association between emotions and functioning scores on Skindex-29, which might indicate that both domains are highly related. Therefore, clinicians should be more attentive to the emotional status of NF1 patients and be more prone to use depression-screening questionnaires such as the PHQ-9 [30, 31] or the Generalized anxiety disorder-7 item scale (GAD 7) [31, 32]. Depression has been described in up to 55% of NF1 [33] patients and is associated with pain intensity and pain interference [34, 35]. A high occurrence of suicide ideation was previously described in NF1 individuals attributable to several psychosocial factors associated with NF1, including depression, anxiety, perceived stress [9, 36], pain, and QoL domains [37, 38]. Improvement of the QoL and emotional status of NF1 individuals is a critical unmet need. Several articles have shown a clear benefit for NF1 individuals to perform face-to-face [39] or online [40] mind-body-based interventions which can be associated or not with pharmacological treatments [41] to improve their emotional status and QoL. Recently, a Relaxation Response Resiliency Program (3RP-NF) including mindfulness, copying, and optimism interventions has shown a durable improvement in QoL among adults with NF1 [42, 43]. Therefore, psychosocial interventions in NF1 individuals should be recommended in the NF1 follow-up protocols to be able to apply for cost coverage/reimbursement by the different health systems worldwide. Otherwise, NF1 individuals with lower income status and at higher risk of psychological burden would be disadvantaged.

As expected, the frequency of the main clinical features of NF1 patients enrolled in this study was like previous literature reports [1, 44, 45]. However, it is interesting that about 1/3 of the patients complained of pruritus and ¼ dizziness, headache, or sleeping troubles. Although those are not life-threatening, they have impacted NF1 patient’s QoL. Pruritus has been described in about 35–69% of patients in prior studies [29, 46] and was described as the more bothersome symptom of NF1 in 14% of patients [2]. Pruritus seems to be associated with the development of new neurofibromas [29]. However, the pathophysiology of pruritus is not well-understood and seems to be complex. Pruritus seems to have neuropathic features [47] but could also be explained by the degranulation of the mast cells which are merged into the cutaneous neurofibromas [48]. There are currently no established guidelines for the treatment of itching in NF1. Doctors treat most patients with emollients, steroid creams, or antihistamines [29] but gabapentine (an antineuropathic agent) or ketotifene (a mast cell stabilizing agent) has also been used. When itching is localized in one or 2 neurofibromas, neurofibroma removal by surgery, carbon dioxide laser [49, 50], or electrodesiccation [51] is considered.

Migraines and non-migraines headaches are frequent in NF1 patients [52, 53]. Migraine can be observed in 34 to 83% of patients with NF1, significantly affecting their QoL [52, 53]. Therefore, patients should receive specific anti-migraine treatment. Sleep troubles such as parasomnias, difficulties in initiation sleep, early morning awakenings, and excessive sleep/wake transition are also frequently described in NF1 patients [54]. A sleep study on 114 NF1 patients identified 69% as being “poor sleepers” and 20% with excessive day sleepiness [54]. As sleep disturbance is a widespread migraine trigger, it might be responsible for some of the headaches described in our patients and may predispose them to depression. Therefore, NF1 patients should benefit from the classical diagnostic and therapeutic strategies [55].

Conclusion

This study highlights the impact of NF1 in the QoL in a cohort of patients from a semi-rural public health primary care area. NF1 shows an essential effect on the emotional status of NF1 patients, which would justify implementing self-esteem strategies to prevent mental health in at-risk individuals. Thus, we identified itching, and sleep troubles that negatively influence the QoL of NF1 patients. Since patients do not perceive these symptoms as NF1-related, patients may not mention them. Therefore, clinicians should actively seek those symptoms to treat them to improve the QoL of their NF1 patients.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1 (22.8KB, xlsx)

Acknowledgements

We thank NF1 patients for their willing participation in this study.

Abbreviations

QoL

Quality of life

NF1

Neurofibromatosis type 1

Authors contribution

IA conceived, planned, and conceptualized the study. IA, ACR, and CLF contributed to acquiring and interpreting clinical data. TFV, IA, ACR, and VM performed statistical analysis. IA wrote the initial manuscript. All authors critically reviewed edited the manuscript, and approved the final version as submitted.

Funding

Open access funding provided by University of Lausanne. A research grant supported by the Conserjería de Sanidad de la Junta de Castilla y León (GRS 571/A/10; 2010-12).

Open access funding provided by University of Lausanne

Data availability

All data supporting the findings of this study are available within the paper and its Supplementary Information.

Declarations

Ethics statement

The Ethical Institutional Review Board Committee of the Complejo Asistencial Universitario de León (approval number 1060) approved the study protocol. All study participants provided written consent.

Consent for publication

All patients provided their written consent to participate in this publication.

Competing interests

All authors state that they have no competing interests to declare. None of the authors accepted any reimbursements, fees, or funds from any organization that may in any way gain or lose financially from the results of this study.

Footnotes

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.Huson SM, Harper PS, Compston DA. Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales. Brain. 1988;111(Pt 6):1355–81. doi: 10.1093/brain/111.6.1355. [DOI] [PubMed] [Google Scholar]
  • 2.Guiraud M, Bouroubi A, Beauchamp R, Bocquet A, Gregoire JM, Rauly-Lestienne I, et al. Cutaneous neurofibromas: patients’ medical burden, current management and therapeutic expectations: results from an online European patient community survey. Orphanet J Rare Dis. 2019;14(1):286. doi: 10.1186/s13023-019-1265-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Cannon A, Chen MJ, Li P, Boyd KP, Theos A, Redden DT, et al. Cutaneous neurofibromas in neurofibromatosis type I: a quantitative natural history study. Orphanet J Rare Dis. 2018;13(1):31. doi: 10.1186/s13023-018-0772-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Verma SK, Riccardi VM, Plotkin SR, Weinberg H, Anderson RR, Blakeley JO, et al. Considerations for development of therapies for cutaneous neurofibroma. Neurology. 2018;91(2 Suppl 1):21–S30. doi: 10.1212/WNL.0000000000005791. [DOI] [PubMed] [Google Scholar]
  • 5.Easton DF, Ponder MA, Huson SM, Ponder BA. An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes. Am J Hum Genet. 1993;53(2):305–13. [PMC free article] [PubMed] [Google Scholar]
  • 6.Szudek J, Birch P, Riccardi VM, Evans DG, Friedman JM. Associations of clinical features in neurofibromatosis 1 (NF1) Genet Epidemiol. 2000;19(4):429–39. doi: 10.1002/1098-2272(200012)19:4<429::AID-GEPI13>3.0.CO;2-N. [DOI] [PubMed] [Google Scholar]
  • 7.Crawford H, North K, Wilson MJ, Berman Y, McKelvey-Martin V, Morrison PJ, et al. Development and preliminary evaluation of the neurofibromatosis type 1 adult quality of life (NF1-AdQoL) questionnaire. Clin Exp Dermatol. 2022;47(2):271–81. doi: 10.1111/ced.14867. [DOI] [PubMed] [Google Scholar]
  • 8.Hamoy-Jimenez G, Elahmar HA, Mendoza M, Kim RH, Bril V, Barnett C. A cross-sectional study of gender differences in quality of life domains in patients with neurofibromatosis type 1. Orphanet J Rare Dis. 2022;17(1):40. doi: 10.1186/s13023-022-02195-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Doser K, Andersen EW, Kenborg L, Dalton SO, Jepsen JRM, Kroyer A, et al. Clinical characteristics and quality of life, depression, and anxiety in adults with neurofibromatosis type 1: a nationwide study. Am J Med Genet A. 2020;182(7):1704–15. doi: 10.1002/ajmg.a.61627. [DOI] [PubMed] [Google Scholar]
  • 10.Kodra Y, Giustini S, Divona L, Porciello R, Calvieri S, Wolkenstein P, et al. Health-related quality of life in patients with neurofibromatosis type 1. A survey of 129 Italian patients. Dermatology. 2009;218(3):215–20. doi: 10.1159/000187594. [DOI] [PubMed] [Google Scholar]
  • 11.Belzeaux R, Lancon C. Neurofibromatosis type 1: psychiatric disorders and quality of life impairment. Presse Med. 2006;35(2):277–80. doi: 10.1016/s0755-4982(06)74570-5. [DOI] [PubMed] [Google Scholar]
  • 12.Bicudo NP, de Menezes Neto BF, da, Silva de Avo LR, Germano CM, Melo DG. Quality of Life in Adults with Neurofibromatosis 1 in Brazil. J Genet Couns. 2016;25(5):1063-74. [DOI] [PubMed]
  • 13.Fertitta L, Bergqvist C, Armand ML, Moryousef S, Ferkal S, Jannic A, et al. Quality of life in neurofibromatosis 1: development and validation of a tool dedicated to cutaneous neurofibromas in adults. J Eur Acad Dermatol Venereol. 2022;36(8):1359–66. doi: 10.1111/jdv.18140. [DOI] [PubMed] [Google Scholar]
  • 14.Yoshida Y, Ehara Y, Koga M, Imafuku S. Health-related quality of life in patients with neurofibromatosis 1 in Japan: a questionnaire survey using EQ-5D-5L. J Dermatol. 2022;49(12):1228–32. doi: 10.1111/1346-8138.16510. [DOI] [PubMed] [Google Scholar]
  • 15.Ren JY, Gu YH, Wei CJ, Huang X, Xu XW, Gu B, et al. Evaluation and factors of quality of life among patients with neurofibromatosis type 1-Associated Craniofacial Plexiform Neurofibromas. J Craniofac Surg. 2020;31(2):347–50. doi: 10.1097/SCS.0000000000006015. [DOI] [PubMed] [Google Scholar]
  • 16.Ferner RE, Thomas M, Mercer G, Williams V, Leschziner GD, Afridi SK, et al. Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the impact of NF1 on quality of life (INF1-QOL) questionnaire. Health Qual Life Outcomes. 2017;15(1):34. doi: 10.1186/s12955-017-0607-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Mahajan A, Patvekar M, Lote S, Deora MS, Poulose D, Gogineni JM, et al. A clinico-epidemiological study of neurofibromatosis type 1 and its relation to quality of life: a cross-sectional study from India. Cureus. 2022;14(2):e22376. doi: 10.7759/cureus.22376. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Page PZ, Page GP, Ecosse E, Korf BR, Leplege A, Wolkenstein P. Impact of neurofibromatosis 1 on quality of life: a cross-sectional study of 176 American cases. Am J Med Genet A. 2006;140(18):1893–8. doi: 10.1002/ajmg.a.31422. [DOI] [PubMed] [Google Scholar]
  • 19.Armand ML, Taieb C, Bourgeois A, Bourlier M, Bennani M, Bodemer C, et al. Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool. Orphanet J Rare Dis. 2019;14(1):94. doi: 10.1186/s13023-019-1067-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Sanagoo A, Jouybari L, Koohi F, Sayehmiri F. Evaluation of QoL in neurofibromatosis patients: a systematic review and meta-analysis study. BMC Neurol. 2019;19(1):123. doi: 10.1186/s12883-019-1338-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Fjermestad KW, Nyhus L, Kanavin OJ, Heiberg A, Hoxmark LB. Health Survey of adults with neurofibromatosis 1 compared to Population Study Controls. J Genet Couns. 2018;27(5):1102–10. doi: 10.1007/s10897-018-0229-5. [DOI] [PubMed] [Google Scholar]
  • 22.Nutakki K, Hingtgen CM, Monahan P, Varni JW, Swigonski NL. Development of the adult PedsQL neurofibromatosis type 1 module: initial feasibility, reliability and validity. Health Qual Life Outcomes. 2013;11:21. doi: 10.1186/1477-7525-11-21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Chren MM, Lasek RJ, Quinn LM, Mostow EN, Zyzanski SJ. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol. 1996;107(5):707–13. doi: 10.1111/1523-1747.ep12365600. [DOI] [PubMed] [Google Scholar]
  • 24.Riccardi VM, Kleiner B. Neurofibromatosis: a neoplastic birth defect with two age peaks of severe problems. Birth Defects Orig Artic Ser. 1977;13(3C):131–8. [PubMed] [Google Scholar]
  • 25.Ablon J. Gender response to neurofibromatosis 1. Soc Sci Med. 1996;42(1):99–109. doi: 10.1016/0277-9536(95)00076-3. [DOI] [PubMed] [Google Scholar]
  • 26.Jones-Caballero M, Penas PF, Garcia-Diez A, Badia X, Chren MM. The Spanish version of Skindex-29. Int J Dermatol. 2000;39(12):907–12. doi: 10.1046/j.1365-4362.2000.00944.x. [DOI] [PubMed] [Google Scholar]
  • 27.Wolkenstein P, Zeller J, Revuz J, Ecosse E, Leplege A. Quality-of-life impairment in neurofibromatosis type 1: a cross-sectional study of 128 cases. Arch Dermatol. 2001;137(11):1421–5. doi: 10.1001/archderm.137.11.1421. [DOI] [PubMed] [Google Scholar]
  • 28.Maguiness S, Berman Y, Rubin N, Dodds M, Plotkin SR, Wong C, et al. Measuring the effect of cutaneous neurofibromas on quality of life in neurofibromatosis type 1. Neurology. 2021;97(7 Suppl 1):25–S31. doi: 10.1212/WNL.0000000000012427. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Fleming J, Morgan O, Wong C, Schlub TE, Berman Y. Characterization of health concerns in people with neurofibromatosis type 1. Mol Genet Genomic Med. 2023;11(1):e2077. doi: 10.1002/mgg3.2077. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606–13. doi: 10.1046/j.1525-1497.2001.016009606.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Buono FD, Sprong ME, Paul E, Martin S, Larkin K, Garakani A. The mediating effects of quality of life, depression, and generalized anxiety on perceived barriers to employment success for people diagnosed with neurofibromatosis type 1. Orphanet J Rare Dis. 2021;16(1):234. doi: 10.1186/s13023-021-01866-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092–7. doi: 10.1001/archinte.166.10.1092. [DOI] [PubMed] [Google Scholar]
  • 33.Cohen JS, Levy HP, Sloan J, Dariotis J, Biesecker BB. Depression among adults with neurofibromatosis type 1: prevalence and impact on quality of life. Clin Genet. 2015;88(5):425–30. doi: 10.1111/cge.12551. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Doorley JD, Greenberg J, Bakhshaie J, Fishbein NS, Vranceanu AM. Depression explains the association between pain intensity and pain interference among adults with neurofibromatosis. J Neurooncol. 2021;154(2):257–63. doi: 10.1007/s11060-021-03826-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Hamoy-Jimenez G, Kim R, Suppiah S, Zadeh G, Bril V, Barnett C. Quality of life in patients with neurofibromatosis type 1 and 2 in Canada. Neurooncol Adv. 2020;2(Suppl 1):i141–i9. doi: 10.1093/noajnl/vdaa003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Wang DL, Smith KB, Esparza S, Leigh FA, Muzikansky A, Park ER, et al. Emotional functioning of patients with neurofibromatosis tumor suppressor syndrome. Genet Med. 2012;14(12):977–82. doi: 10.1038/gim.2012.85. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Cohen JS, Biesecker BB. Quality of life in rare genetic conditions: a systematic review of the literature. Am J Med Genet A. 2010;152A(5):1136–56. doi: 10.1002/ajmg.a.33380. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Vranceanu AM, Merker VL, Plotkin SR, Park ER. The relaxation response resiliency program (3RP) in patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis: results from a pilot study. J Neurooncol. 2014;120(1):103–9. doi: 10.1007/s11060-014-1522-2. [DOI] [PubMed] [Google Scholar]
  • 39.Zale EL, Pierre-Louis C, Macklin EA, Riklin E, Vranceanu AM. The impact of a mind-body program on multiple dimensions of resiliency among geographically diverse patients with neurofibromatosis. J Neurooncol. 2018;137(2):321–9. doi: 10.1007/s11060-017-2720-5. [DOI] [PubMed] [Google Scholar]
  • 40.Lester EG, Fishbein NS, Peterson A, Vranceanu AM. Early feasibility testing of a web-based mind-body resiliency program for adults with neurofibromatosis: the NF-Web study. PEC Innov. 2022;1:100076. doi: 10.1016/j.pecinn.2022.100076. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Houpt AC, Schwartz SE, Coover RA. Assessing Psychiatric Comorbidity and pharmacologic treatment patterns among patients with neurofibromatosis type 1. Cureus. 2021;13(12):e20244. doi: 10.7759/cureus.20244. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Vranceanu AM, Manglani HR, Choukas NR, Kanaya MR, Lester E, Zale EL, et al. Effect of mind-body skills training on quality of life for geographically diverse adults with neurofibromatosis: a fully remote Randomized Clinical Trial. JAMA Netw Open. 2023;6(6):e2320599. doi: 10.1001/jamanetworkopen.2023.20599. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.VA G. Mindfulness, coping, and optimism as mechanisms of change in the 3RP-NF intervention. J Clin Psychol. 2024;80(2)):456–70. [DOI] [PMC free article] [PubMed]
  • 44.McGaughran JM, Harris DI, Donnai D, Teare D, MacLeod R, Westerbeek R, et al. A clinical study of type 1 neurofibromatosis in north west England. J Med Genet. 1999;36(3):197–203. [PMC free article] [PubMed] [Google Scholar]
  • 45.Riccardi VM. Type 1 neurofibromatosis and the pediatric patient. Curr Probl Pediatr. 1992;22(2):66–106. doi: 10.1016/0045-9380(92)90053-2. [DOI] [PubMed] [Google Scholar]
  • 46.Brenaut E, Nizery-Guermeur C, Audebert-Bellanger S, Ferkal S, Wolkenstein P, Misery L, et al. Clinical characteristics of Pruritus in neurofibromatosis 1. Acta Derm Venereol. 2016;96(3):398–9. doi: 10.2340/00015555-2241. [DOI] [PubMed] [Google Scholar]
  • 47.Misery L, Brenaut E, Le Garrec R, Abasq C, Genestet S, Marcorelles P, et al. Neuropathic pruritus. Nat Rev Neurol. 2014;10(7):408–16. doi: 10.1038/nrneurol.2014.99. [DOI] [PubMed] [Google Scholar]
  • 48.Ortonne N, Wolkenstein P, Blakeley JO, Korf B, Plotkin SR, Riccardi VM, et al. Cutaneous neurofibromas: current clinical and pathologic issues. Neurology. 2018;91(2 Suppl 1):5–S13. doi: 10.1212/WNL.0000000000005792. [DOI] [PubMed] [Google Scholar]
  • 49.Meni C, Sbidian E, Moreno JC, Lafaye S, Buffard V, Goldzal S, et al. Treatment of neurofibromas with a carbon dioxide laser: a retrospective cross-sectional study of 106 patients. Dermatology. 2015;230(3):263–8. doi: 10.1159/000368078. [DOI] [PubMed] [Google Scholar]
  • 50.Peltonen S, Jannic A, Wolkenstein P. Treatment of cutaneous neurofibromas with carbon dioxide laser: technique and patient experience. Eur J Med Genet. 2022;65(1):104386. doi: 10.1016/j.ejmg.2021.104386. [DOI] [PubMed] [Google Scholar]
  • 51.Lutterodt CG, Mohan A, Kirkpatrick N. The use of electrodessication in the treatment of cutaneous neurofibromatosis: a retrospective patient satisfaction outcome assessment. J Plast Reconstr Aesthet Surg. 2016;69(6):765–9. doi: 10.1016/j.bjps.2016.03.024. [DOI] [PubMed] [Google Scholar]
  • 52.DiMario FJ, Jr, Langshur S. Headaches in patients with neurofibromatosis-1. J Child Neurol. 2000;15(4):235–8. doi: 10.1177/088307380001500406. [DOI] [PubMed] [Google Scholar]
  • 53.Afridi SK, Leschziner GD, Ferner RE. Prevalence and clinical presentation of headache in a National Neurofibromatosis 1 service and impact on quality of life. Am J Med Genet A. 2015;167A(10):2282–5. doi: 10.1002/ajmg.a.37186. [DOI] [PubMed] [Google Scholar]
  • 54.Leschziner GD, Golding JF, Ferner RE. Sleep disturbance as part of the neurofibromatosis type 1 phenotype in adults. Am J Med Genet A. 2013;161A(6):1319–22. doi: 10.1002/ajmg.a.35915. [DOI] [PubMed] [Google Scholar]
  • 55.Pavlova M. Circadian Rhythm Sleep-Wake disorders. Continuum (Minneap Minn) 2017;23(4, Sleep Neurology):1051–63. doi: 10.1212/CON.0000000000000499. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Material 1 (22.8KB, xlsx)

Data Availability Statement

All data supporting the findings of this study are available within the paper and its Supplementary Information.

Articles from Orphanet Journal of Rare Diseases are provided here courtesy of BMC

RESOURCES